Research Analysts’ Recent Ratings Updates for Valeant Pharmaceuticals International (VRX)

Several analysts have recently updated their ratings and price targets for Valeant Pharmaceuticals International (NYSE: VRX):

  • 9/1/2017 – Valeant Pharmaceuticals International was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/29/2017 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Mizuho. They now have a $7.00 price target on the stock, down previously from $8.00.
  • 8/29/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $23.00 price target on the stock.
  • 8/24/2017 – Valeant Pharmaceuticals International was downgraded by analysts at Vetr from a “strong-buy” rating to a “sell” rating. They now have a $13.30 price target on the stock.
  • 8/21/2017 – Valeant Pharmaceuticals International was given a new $17.00 price target on by analysts at HC Wainwright. They now have a “hold” rating on the stock.
  • 8/21/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $45.00 price target on the stock.
  • 8/21/2017 – Valeant Pharmaceuticals International was given a new $19.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 8/16/2017 – Valeant Pharmaceuticals International was given a new $23.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida.””
  • 8/10/2017 – Valeant Pharmaceuticals International was given a new $14.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 8/10/2017 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $9.00 price target on the stock.
  • 8/10/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $35.00 price target on the stock.
  • 8/10/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $18.00 price target on the stock.
  • 8/10/2017 – Valeant Pharmaceuticals International had its “neutral” rating reaffirmed by analysts at Rodman & Renshaw. They now have a $17.00 price target on the stock.
  • 8/10/2017 – Valeant Pharmaceuticals International had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $16.00 price target on the stock.
  • 8/9/2017 – Valeant Pharmaceuticals International was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a “sell” rating on the stock.
  • 8/9/2017 – Valeant Pharmaceuticals International was given a new $17.00 price target on by analysts at HC Wainwright. They now have a “hold” rating on the stock.
  • 8/9/2017 – Valeant Pharmaceuticals International had its price target raised by analysts at Scotiabank from $14.00 to $16.00. They now have a “sector perform” rating on the stock.
  • 8/9/2017 – Valeant Pharmaceuticals International had its “underperform” rating reaffirmed by analysts at Mizuho. They now have a $8.00 price target on the stock.
  • 8/6/2017 – Valeant Pharmaceuticals International was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Valeant Pharmaceuticals International was given a new $14.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 8/3/2017 – Valeant Pharmaceuticals International had its price target raised by analysts at Royal Bank Of Canada from $19.00 to $21.00. They now have a “sector perform” rating on the stock.
  • 7/31/2017 – Valeant Pharmaceuticals International was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/30/2017 – Valeant Pharmaceuticals International is no longer covered by analysts at Wells Fargo & Company.
  • 7/28/2017 – Valeant Pharmaceuticals International was given a new $23.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/27/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $15.00 price target on the stock.
  • 7/27/2017 – Valeant Pharmaceuticals International was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company reduced its debt by $4.3 billion since the first quarter of 2016.The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Shares have underperformed the broader industry.”
  • 7/17/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $35.00 price target on the stock.
  • 7/17/2017 – Valeant Pharmaceuticals International was given a new $19.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 7/17/2017 – Valeant Pharmaceuticals International was given a new $10.00 price target on by analysts at J P Morgan Chase & Co. They now have a “hold” rating on the stock.
  • 7/14/2017 – Valeant Pharmaceuticals International had its “underweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $10.00 price target on the stock.
  • 7/14/2017 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Company.
  • 7/14/2017 – Valeant Pharmaceuticals International had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $18.00 price target on the stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 14.19 on Tuesday. Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $28.59. The firm has a 50-day moving average of $14.79 and a 200-day moving average of $13.20. The firm’s market capitalization is $4.95 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same period last year, the firm earned ($0.88) EPS. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. On average, equities research analysts forecast that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

In other news, Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 5.87% of the stock is owned by company insiders.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply